New RIS becomes available University of Utah signs with Philips’ iSite
Examining new mammograms in the context of old ones can play a critical role in finding breast cancer. Software that makes these comparisons easier will soon be commercially available from Hologic through its now FDA-cleared R2 DigitalNow HD software application. The new product turns digital images made from prior screen-film mammograms into DICOM images that closely resemble mammograms acquired digitally. The software adapts each digitized film image to a contrast and tissue intensity similar to those seen with mammography systems. It also embeds in the image a series of look-up tables that allow workstations conforming to Integrating the Healthcare Enterprise guidelines to make less evident regions of density more apparent in the digitized images.
A low-cost RIS from Clear Innova has entered the market with features that support patient scheduling; recordkeeping for documents, forms, dictation, and images; and billing. The Origin RIS allows referring physicians to order and schedule imaging studies, check the status of orders, and obtain reports from any location via a web browser.
Philips has signed an eight-year iSite PACS replacement deal with University of Utah Health Care, the region's only academic healthcare system. The deal coincides with the replacement by University Health Care of a legacy PACS with iSite, which went live in January.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Mammography Study: AI Facilitates Greater Accuracy and Longer Fixation Time on Suspicious Areas
July 8th 2025While noting no differences in sensitivity, specificity or reading time with adjunctive AI for mammography screening, the authors of a new study noted a 4 percent higher AUC and increased fixation time on lesion regions.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.